180one congratulates CereVasc on the appointment of Janelle Arrambide as the Director of Clinical Development. CereVasc is a medical device company focused on the development of novel, minimally invasive treatments for patients with neurological diseases. The Company’s first product, the eShunt™ System, has been developed to treat hydrocephalus, a potentially life-threatening disease also known as “water on the brain.” The eShunt System has the potential to disrupt a 60-year-old standard of care that is fraught with high failure and complication rates that typically result in patients requiring multiple revision surgeries over the span of their treatment.
Janelle brings very relevant Class III medical device experience to CereVasc in the fields of neurosurgery and drug delivery and has an impressive track record of accomplishing clinical milestones. With a robust background in clinical trial management, Janelle will be an excellent addition to the CereVasc team during this critical stage in their evolution.
180one was proud to partner with CereVasc on this critical new hire and we wish Janelle all the best with her new role!
Head on over to our Placements/Opportunities page to see what else we’ve been working on!